© 2022 Celltex Therapeutics Corporation. All rights reserved.
Dr. Derek W. Guillory, Founder and Medical Director of Root Causes Medicine in San Antonio and Principal Investigator for Celltex’s upcoming clinical trial was recently brought on as a guest of the Erick Erickson Show on WSB Radio.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. On March 21st, 2020, Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs) in the US.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. The journal Aging & Disease has recently reported on a study that has proven transplantation of mesenchymal stem cells has improved the outcome of 7 patients diagnosed with COVID-19 Pneumonia in Bejing, China.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells.
Learn MoreThe COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. Celltex is continuing to monitor and participate in this promising research.
Learn MoreWe have been closely monitoring the guidelines set forth from the Centers for Disease Control (CDC) and the World Health Organization (WHO) in response to COVID-19. The safety and health of our team, clients and community is extremely important to us and because of this, we are taking proper precautions in our corporate office and lab environment.
Learn More